Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01092416 · ClinicalTrials.gov registry record · NA

Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions

A NA study, sponsored by Abbott Medical Devices.

Completed
Registry status
NA
Development phase
443
Enrollment target

NCT01092416 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 443 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01092416, a NA study, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
NA
Development phase
443 participants
Enrollment target

Study Summary

This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects. Study is going to enroll up to 429 subjects in up to 50 U.S. study sites. The primary safety endpoint is 30-day MACE and primary efficacy endpoint is procedural success. All subjects will be treated with the orbital atherectomy system and adjunctive stent. All subjects will be followed in clinic at 30 days. Additionally, all subjects will have an annual phone call or clinical follow up at each anniversary until study is closed.

Interventions

  • DEVICE Diamondback 360 Orbital Atherectomy System

Trial Details

FieldValue
Enrollment Target 443 participants
Start Date 2010-05
Est. Completion 2016-01
Phase NA

Sponsor

Abbott Medical Devices

261 total trials

What the Registry Record Tells You About NCT01092416

The ClinicalTrials.gov registry entry for NCT01092416 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 443 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Diamondback 360 Orbital Atherectomy System is the first listed.

NCT01092416 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01092416 about?

NCT01092416 is a clinical study titled "Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions". This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects. Study is going to enroll up to 429 subjects in up to 50 U.S. study sites. The primary safety endpoint is 30-day MACE and...

What is the current status of trial NCT01092416?

This trial is currently completed. It is a NA study. The enrollment target is 443 participants. The study started on 2010-05. Estimated completion is 2016-01.

What interventions are being tested in trial NCT01092416?

The interventions under investigation include: Diamondback 360 Orbital Atherectomy System (DEVICE).

Who is sponsoring clinical trial NCT01092416?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.